Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test

30 de junio de 2026 actualizado por: bioLytical Laboratories

A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of iStatis Gonorrhea Antigen Test by Trained Personnel at Near-Patient or Point-of-Care Settings

The objective of this study is to evaluate the performance, usability, and contrived result interpretation of iStatis Gonorrhea Antigen Test (iStatis Gonorrhea Test) in the intended near-patient or point-of-care setting by trained personnel.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

The study is designed to evaluate iStatis Gonorrhea Test performance when used by trained personnel as follows:

  1. A method comparison will be performed to determine the diagnostic sensitivity and specificity of the iStatis Gonorrhea Test compared to a reference test that is an approved, current on-market Gonorrhea/Chlamydia combo assay, Cobas CT/NG.
  2. To evaluate the usability of iStatis Gonorrhea Test by means of assessing user experience via a questionnaire in combination with the success in performing the test. A minimum of 15 intended users to participate in the usability evaluation.
  3. To evaluate and document whether intended users (trained personnel), a minimum of 15 intended users across a minimum of three (3) sites, can successfully interpret contrived iStatis Gonorrhea Test results that include - strong positive, weak positive, negative and a range of invalid results.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

650

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

  • Sudáfrica
    • Gauteng
      • Johannesburg, Gauteng, Sudáfrica, 2193
        • Reclutamiento
        • Epicentre Health Research (Johannesburg)
        • Contacto:
    • KwaZulu-Natal
      • Durban, KwaZulu-Natal, Sudáfrica, 3650
        • Reclutamiento
        • Epicentre Health Research
        • Contacto:
    • Western Cape
      • Cape Town, Western Cape, Sudáfrica, 7925
        • Reclutamiento
        • Epicentre Health Research (Cape Town)
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria

  • Age > 16 years
  • Subject (or legally authorized representative) is willing to provide written informed consent before any study procedures
  • Female gender
  • Subject is able and willing to provide vaginal swab specimen for study procedures (3-4 swabs)
  • Subject can complete the required testing on the allocated testing day
  • Subject can speak, read, and write English
  • Subject's demographic information, risk factors, and symptoms are available and can be recorded on case report forms
  • Subject agrees to comply with study procedures and sample collection for both the investigational device and the reference method
  • Subject is willing to participate in the study site's standard-of-care Gonorrhea counselling and testing program and receive standard-of-care test results, as required and applicable

  • Subject is indicated for sexually transmitted infection testing for one or more of the following reasons:

    • At risk of Gonorrhea, such as recent unprotected intercourse, multiple or new partners within < 60 days, known exposure to an infected partner, or prior STI history
    • Having signs and/or symptoms suggestive of Gonorrhea (e.g., urethral, vaginal, rectal, or pharyngeal discharge; dysuria; pelvic or lower-abdominal pain; sore throat; or rectal discomfort)
    • Undergoing routine or opportunistic STI screening, including family-planning, antenatal, or sexual-health clinic visits
    • Undergoing re-testing (test-of-cure) > 7 days after completion of Gonorrhea treatment and clinically stable
    • Undergoing co-testing for other STIs where Gonorrhea testing is part of a broader diagnostic panel

Exclusion Criteria

  • Subject 15 years of age or younger
  • Male gender
  • Female currently menstruating
  • Subject is unable or unwilling to provide informed consent
  • Subject is medically unstable or has psychiatric condition(s) that pose a risk or prevent study compliance
  • Subject is unable to provide paired samples for reference testing
  • Subject requires urgent antimicrobial treatment before specimen collection
  • Subject received systemic or topical antibiotics active against Gonorrhea within the previous 7 days
  • Subject used topical intravaginal or rectal antiseptics within 48 hours prior to study sampling
  • Previously enrolled for the same infection episode
  • Anatomical or clinical contraindication to study sampling (e.g., severe cervical pathology)
  • Recent urogenital procedure (e.g., cystoscopy, lavage) < 72 hours before study sampling
  • Subject belongs to a protected group excluded by local ethics (e.g., incarcerated persons), unless explicitly approved by the EC/IRB
  • Any condition that, in the opinion of trained personnel or study staff, would make the participant unsuitable or unsafe for enrolment, interfere with completion of assessments, consent, or questionnaires, or bias study outcomes
  • Subject is participating in another interventional clinical study within 30 days that could interfere with study results

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Poner en pantalla
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: iStatis Gonorrhea Test Performance (Operator-collected swabs)
Operator-collected vaginal swabs will be tested on the iStatis Gonorrhea Test
Dispositivo: iStatis Gonorrhea Antigen Test
Vaginal swabs are tested on the iStatis Gonorrhea Antigen Test
Experimental: iStatis Gonorrhea Test Performance (Self-collected swabs)
Self-collected vaginal swabs will be tested on the iStatis Gonorrhea Test. Participants assigned to the self-collection arm of the study will complete the self-collection Usability Questionnaire
Dispositivo: iStatis Gonorrhea Antigen Test
Vaginal swabs are tested on the iStatis Gonorrhea Antigen Test
Sin intervención: Reference Test to evaluate iStatis Performance
Vaginal swabs collected for reference testing will be tested using the Cobas CT/NG reference assay to determine the gonorrhea infection status of participants.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Performance Evaluation
Periodo de tiempo: 3 months
The performance between iStatis Gonorrhea Test and the reference test result for vaginal swabs (operator-collected and self-collected) will be calculated for all sites combined. Diagnostic sensitivity and specificity values and 95% CIs will be calculated for all subjects combined. The percentage of invalids (tests that fail to produce a control dot with accurate use) will be identified and reported.
3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
iStatis Gonorrhea Test usability evaluation
Periodo de tiempo: 3 months
Overall test usability and self collection usability will be determined via a questionnaire completed by trained personnel who used the device during testing and study participants that performed sample self-collection respectively. The usability questionnaire will use a scale of one (1) to 5 (1 - very difficult/very unlikely to 5 - very easy/very likely), with a rating of 3 being satisfactory.
3 months
iStatis Gonorrhea Test contrived result interpretation evaluation
Periodo de tiempo: 3 months
Trained operators will evaluate a panel of contrived (mock) iStatis devices. These devices are designed to represent a comprehensive range of test outcomes, including strong positives, weak positives, negatives and invalid results. Operators will interpret the results of the mock devices and record their interpretations which will be compared to the correct interpretation of the device.
3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

bioLytical Laboratories

Colaboradores

Epicentre

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de noviembre de 2025

Finalización primaria (Estimado)

1 de septiembre de 2026

Finalización del estudio (Estimado)

1 de enero de 2027

Fechas de registro del estudio

Enviado por primera vez

21 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

29 de abril de 2026

Publicado por primera vez (Actual)

6 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

2 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

30 de junio de 2026

Última verificación

1 de abril de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • CLS-009A

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir